<div id=toc></div>

# Table of Contents

- [physics.med-ph](#physics.med-ph) [Total: 1]
- [q-bio.BM](#q-bio.BM) [Total: 1]


<div id='physics.med-ph'></div>

# physics.med-ph [[Back]](#toc)

### [1] [Autonomous Uncertainty Quantification for Computational Point-of-care Sensors](https://arxiv.org/abs/2512.21335)
*Artem Goncharov, Rajesh Ghosh, Hyou-Arm Joung, Dino Di Carlo, Aydogan Ozcan*

Main category: physics.med-ph

TL;DR: 本文提出了一种用于计算型即时诊断传感器（POC）的自主不确定性量化技术，通过蒙特卡洛dropout (MCDO) 识别并排除高不确定性的错误预测，显著提高了诊断的灵敏度和可靠性。


<details>
  <summary>Details</summary>
Motivation: 基于神经网络的诊断模型容易产生幻觉和错误预测，可能导致误诊和不准确的临床决策。因此，需要一种自主的不确定性量化技术来提高计算型POC传感器的可靠性。

Method: 研究人员将蒙特卡洛dropout (MCDO) 不确定性量化方法整合到基于纸基垂直流动分析 (xVFA) 平台的诊断流程中，该平台用于快速诊断莱姆病。xVFA平台结合了可抛弃的纸基试剂、手持式光学读取器和基于神经网络的推断算法。

Result: 通过使用新的患者样本进行盲测，诊断灵敏度从88.2%提高到95.7%，表明MCDO-基于不确定性量化有效地增强了神经网络驱动的计算型POC传感器的稳健性。

Conclusion: 自主不确定性量化技术，特别是MCDO方法，可以显著提高计算型POC传感器的诊断准确性和可靠性，使其更适用于资源有限的环境和临床实践。

Abstract: Computational point-of-care (POC) sensors enable rapid, low-cost, and accessible diagnostics in emergency, remote and resource-limited areas that lack access to centralized medical facilities. These systems can utilize neural network-based algorithms to accurately infer a diagnosis from the signals generated by rapid diagnostic tests or sensors. However, neural network-based diagnostic models are subject to hallucinations and can produce erroneous predictions, posing a risk of misdiagnosis and inaccurate clinical decisions. To address this challenge, here we present an autonomous uncertainty quantification technique developed for POC diagnostics. As our testbed, we used a paper-based, computational vertical flow assay (xVFA) platform developed for rapid POC diagnosis of Lyme disease, the most prevalent tick-borne disease globally. The xVFA platform integrates a disposable paper-based assay, a handheld optical reader and a neural network-based inference algorithm, providing rapid and cost-effective Lyme disease diagnostics in under 20 min using only 20 uL of patient serum. By incorporating a Monte Carlo dropout (MCDO)-based uncertainty quantification approach into the diagnostics pipeline, we identified and excluded erroneous predictions with high uncertainty, significantly improving the sensitivity and reliability of the xVFA in an autonomous manner, without access to the ground truth diagnostic information of patients. Blinded testing using new patient samples demonstrated an increase in diagnostic sensitivity from 88.2% to 95.7%, indicating the effectiveness of MCDO-based uncertainty quantification in enhancing the robustness of neural network-driven computational POC sensing systems.

</details>


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [2] [Clever Hans in Chemistry: Chemist Style Signals Confound Activity Prediction on Public Benchmarks](https://arxiv.org/abs/2512.20924)
*Andrew D. Blevins, Ian K. Quigley*

Main category: q-bio.BM

TL;DR: 该研究表明，机器学习模型在预测生物活性时，可能并非真正理解化学结构与活性之间的关系，而是通过学习化学家的风格偏好（例如，偏爱的骨架和靶点）来预测，类似于心理学中的“克莱弗·汉斯”效应。


<details>
  <summary>Details</summary>
Motivation: 研究动机是探究机器学习模型是否会利用化学家的风格偏好而非真正的化学结构-活性关系来预测生物活性。作者受到一位化学家能够仅凭分子结构识别另一位化学家的风格的启发，怀疑模型可能存在类似现象。

Method: 研究采用两阶段实验：第一阶段，训练一个模型预测化合物的作者，在基于骨架分割的情况下，实现了60%的top-5准确率；第二阶段，训练一个仅使用蛋白质ID和预测的作者概率向量的活性模型，完全不使用分子描述符，结果表明该模型性能与简单的基于ECFP+蛋白质的基线模型相当。

Result: 活性模型在不使用分子结构信息的情况下，仅通过作者概率向量和蛋白质ID就能达到与传统模型相当的预测性能，表明模型能够通过推断化学家的目标和偏好来预测生物活性，揭示了“克莱弗·汉斯”效应在药物化学中的存在。

Conclusion: 该研究强调了数据集构建中化学家风格信号的潜在影响，并建议采用作者无关的分割方法、对抗性去偏见和跨实验室复制等措施，以减少模型对化学家意图的依赖，从而更准确地评估模型对化学和生物学知识的理解。

Abstract: Can machine learning models identify which chemist made a molecule from structure alone? If so, models trained on literature data may exploit chemist intent rather than learning causal structure-activity relationships. We test this by linking CHEMBL assays to publication authors and training a 1,815-class classifier to predict authors from molecular fingerprints, achieving 60% top-5 accuracy under scaffold-based splitting. We then train an activity model that receives only a protein identifier and an author-probability vector derived from structure, with no direct access to molecular descriptors. This author-only model achieves predictive power comparable to a simple baseline that has access to structure. This reveals a "Clever Hans" failure mode: models can predict bioactivity largely by inferring chemist goals and favorite targets without requiring a lab-independent understanding of chemistry. We analyze the sources of this leakage, propose author-disjoint splits, and recommend dataset practices to decouple chemist intent from biological outcomes.

</details>
